International Congress.Drug resistance in ovarian cancer:bomarkers andtreatments.

Ovarian cancer is the fifth most common cause of death from cancer and the most common cause of death from gynecologic cancer in women of all ages in the Western world. This primarily reflects the fact that there are no early warning signs, and most patients with epithelial ovarian cancer present an advanced stage of the pathology at the time of diagnosis. Efforts to improve survival continue to focus on the development of more effective systemic therapies and on the identification of biomarkers for early diagnosis and drug efficacy. Early diagnosis is crucial, marking the difference between a 95 percent survival rate for cancers found at the earliest stage and 20 percent survival among patients diagnosed with advanced disease. New and higher quality therapies are at the frontiers The area is fragmented and need to be more coordinated with the clinical aspects. Disciplines such as drug discovery, drug safety, technological aspects, proteomics, system biology, pharmacogenetics, patient selection, clinical validations and applications are essential and strictly connected.In this event we would like to point out these aspects and the need to technically and scientifically link the different disciplines under the same aim of identifying a compact strategy to combat ovarian cancer. Biomakers and treatments are the guidelines of the meeting and expert from different area will present their work and will create a platform to avenue translational research in this area. LIGHTS and OVCAD EU projects of the 6th framework program will guide the events and will take the opportunity to present their results in a special session.Target audience is every scientist working in the area in the surrounding of chemistry, biology and clinic focused on OC.